drugset / Trial / NCT00390091
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
RandomizedParallel-groupSingle-blindDiagnostic
Summary
The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.
Timeline
- Start
- 2006-09
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abetimus | Unknown | 100 mg | — |
| Subject | Abetimus | Unknown | 300 mg | — |
| Subject | Abetimus | Unknown | 900 mg | — |